The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design. Gap type: contradiction Source paper: Synergy between amyloid-β and tau in Alzheimer's disease. (2020, Nature neuroscience, PMID:32778792)
Landscape Summary: Why have anti-Aβ clinical trials failed despite the established role of Aβ in AD pathogenesis? is a 0.88 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
Why have anti-Aβ clinical trials failed despite the established role of Aβ in AD pathogenesis? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: